drug

ACP-001

1 story · latest Aug 13, 2026

Status: Investigational
Brand: Transcon Hgh
Trials: 3 registered trials in coverage

Relationships

Developed by Ascendis Pharma A/S

Timeline

Ascendis Pharma posts Q2 2026 revenue of €315 million, up 105% year over year

Aug 13Clinical readoutAscendis Pharma A/S navepegritide

Biotech intelligence from primary sources. Every story is an original summary of a public record, linked to its source. Not investment advice.

Terms Privacy hello@readthrough.news

readthrough is a product of JAMN Ventures, LLC.